USANA HEALTH SCIENCES INC (USNA) Form 8-K — Nov 3, 2026
USANA reported Q3 2026 net sales of $206 million, down 4% year-over-year, with a net loss of $(5.6) million ($(0.30) per diluted share) that narrowed from $(0.36) a year ago. Hiya Active Monthly Subscribers jumped 18% sequentially to 195,500 and Hiya returned to year-over-year sales growth, while Core Nutritional active customers fell 8% to 356,000. The company cut its fiscal 2026 outlook: consolidated net sales now approaching $900 million versus $910 million previously, Adjusted diluted EPS of $0.55 versus $0.76, and Adjusted EBITDA of $77 million versus $80.5 million (as corrected).
Key figures
- Revenue
- 205885000
- Guidance
- FY2026 updated: consolidated net sales approaching $900M (prior $910M), net loss $(16)M (prior $(11)M), diluted EPS $(0.90) (prior $(0.61)), Adjusted diluted EPS $0.55 (prior $0.76), Adjusted EBITDA $77M (prior $80.5M as corrected)
- Revenue Yoy
- -4%
- Total Assets
- 708470000
- Cash Position
- 178915000
- Inventory
- 93311000
- Gross margin
- 76.3%
- Hiya net sales
- 31545000
- Rise net sales
- 3643000
- Free cash flow q3
- 8443000
- Adjusted ebitda q3
- 12100000
- Free cash flow ytd
- 35721000
- Adjusted ebitda yoy
- -13%
- Hiya active subscribers
- 195500
- Core nutritional net sales
- 170697000
- Remaining buyback authorization
- 34000000
- Core nutritional active customers
- 356000
- Hiya subscriber sequential growth
- +18%
- Q2 2026 adjusted ebitda correction
- $27.8M corrected to $21.7M (non-GAAP only)
- Core nutritional active customers yoy
- -8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.